Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche bearbeiten
Filter bei nächster Suche beibehalten
format_facet:"Elektronische Ressource"
collection:"CTG"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=collection%3ACTG&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22ritonavir%22&type0%5B%5D=Subject&op0%5B%5D=OR
/vufind/Search/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=collection%3ACTG&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22ritonavir%22&type0%5B%5D=Subject&op0%5B%5D=OR
Search /vufind/Search2/Results?filter%5B%5D=format_facet%3A%22Elektronische+Ressource%22&filter%5B%5D=collection%3ACTG&join=AND&bool0%5B%5D=AND&lookfor0%5B%5D=%22ritonavir%22&type0%5B%5D=Subject&op0%5B%5D=OR
PubPharm (45)
1
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years old : Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication - BILOLDER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Substitution current ARV therapy by BIKTARVY in hiv infected patients over 65 years old : Switch to Tenofovir Alafenamide (TAF), Emtricitabine (FTC), Bictegravir (BIC)(Biktarvy®) in HIV-1-infected patients over 65 years old at risk of polymedication - BILOLDER
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial : Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
4
Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection : Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
5
Virological outcome and metabolic effect after switching from ritonavir-boosted protease inhibitor to dolutegravir-bas regimen in virologically suppressed patients living with HIV : Virological outcome and metabolic effect after switching from ritonavir-boosted protease inhibitor to dolutegravir-bas regimen in virologically suppressed patients living with HIV
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
6
Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks: a prospective, open-label, randomized controlled trial : Virological response of switching tenofovir disoproxil fumarate(TDF)-based regimen to abacavir(ABC)-based regimen versus lopinavir/ritonavir(LPV/r) plus lamivudine(3TC) in HIV-infected patients with TDF-induced nephrotoxicity at 24 weeks : a prospect
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
7
Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection : Randomized controlled trial of a comparison between ritonavir-boosted atazanavir with tenofovir plus emtricitabine versus rilpivirine with tenofovir plus emtricitabine in occupational post-exposure prophylaxis for HIV infection
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
8
Virological outcome and metabolic effect after switching from ritonavir-boosted protease inhibitor to dolutegravir-bas regimen in virologically suppressed patients living with HIV : Virological outcome and metabolic effect after switching from ritonavir-boosted protease inhibitor to dolutegravir-bas regimen in virologically suppressed patients living with HIV
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
9
A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR) : A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR) - D-LIVR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A research study to evaluate the efficacy and safety of the study drug named Lonafarnib administrated with Ritonavir, in patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR) : A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID with and without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared with PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected with Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)ide Therapy (D-LIVR) - D-LIVR
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
5
Nächster »
[5]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Medienart: E-Ressourcen
Medienart
45
Aufsätze
45
E-Artikel
E-Ressourcen
Zeitschriftentitel
42
WHO International Clinical Trials Registry Plat...
3
ClinicalTrials.gov
Thema
45
610
45
Study Type: Interventional
22
Phase: Phase 3
20
Recruitment Status: Authorised-recruitment may ...
16
Medical Condition: The proposed indication for ...
10
Recruitment Status: Not yet recruiting
6
Phase: Phase 4
6
Recruitment Status: Completed
6
Recruitment Status: Recruiting
2
Medical Condition: El propósito del estudio es...
2
Medical Condition: GW873140 in combination with...
2
Medical Condition: GW873140 in combination with...
2
Medical Condition: GW873140 in combination with...
2
Medical Condition: HIV-1-infected patientAge > ...
2
Medical Condition: HIV-infected patients on sta...
2
Medical Condition: Hypercholesterolaemia associ...
2
Medical Condition: Occupational post-exposu...
2
Medical Condition: Tenofovir disoproxil fumarat...
2
Medical Condition: The proposed indication for ...
2
Medical Condition: The purpose of this Phase II...
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
27
2020-
18
2010-2019
Erscheinungsjahr(e)
Von:
Bis:
Sprache
43
Englisch
2
Unbestimmt
Haven't found what you're looking for?
Wird geladen...